Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 525

1.

Functional connectomics of affective and psychotic pathology.

Baker JT, Dillon DG, Patrick LM, Roffman JL, Brady RO Jr, Pizzagalli DA, Öngür D, Holmes AJ.

Proc Natl Acad Sci U S A. 2019 Apr 30;116(18):9050-9059. doi: 10.1073/pnas.1820780116. Epub 2019 Apr 15.

2.

Cerebellar-Prefrontal Network Connectivity and Negative Symptoms in Schizophrenia.

Brady RO Jr, Gonsalvez I, Lee I, Öngür D, Seidman LJ, Schmahmann JD, Eack SM, Keshavan MS, Pascual-Leone A, Halko MA.

Am J Psychiatry. 2019 Jan 30:appiajp201818040429. doi: 10.1176/appi.ajp.2018.18040429. [Epub ahead of print]

PMID:
30696271
3.

Correction: Individual-specific functional connectivity markers track dimensional and categorical features of psychotic illness.

Wang D, Li M, Wang M, Schoeppe F, Ren J, Chen H, Öngür D, Brady RO Jr, Baker JT, Liu H.

Mol Psychiatry. 2019 Jan 16. doi: 10.1038/s41380-018-0340-x. [Epub ahead of print]

PMID:
30651603
4.

Individual-specific functional connectivity markers track dimensional and categorical features of psychotic illness.

Wang D, Li M, Wang M, Schoeppe F, Ren J, Chen H, Öngür D, Brady RO Jr, Baker JT, Liu H.

Mol Psychiatry. 2018 Nov 15. doi: 10.1038/s41380-018-0276-1. [Epub ahead of print] Erratum in: Mol Psychiatry. 2019 Jan 16;:.

5.

Extraovarian sex cord tumor with annular tubules discovered arising from a leiomyoma.

Jaegle WT, Keyser EA, Messersmith L, Brady RO, Miller C.

Gynecol Oncol Rep. 2018 Jul 2;26:17-20. doi: 10.1016/j.gore.2018.06.013. eCollection 2018 Nov.

6.

Lithium + Colchicine: A Potential Strategy to Reduce Pro-inflammatory Effects of Lithium Treatment.

Mooney JJ, Brady RO.

J Clin Psychopharmacol. 2018 Feb;38(1):80-85. doi: 10.1097/JCP.0000000000000830. Review.

PMID:
29232311
7.

Vorinostat suppresses hypoxia signaling by modulating nuclear translocation of hypoxia inducible factor 1 alpha.

Zhang C, Yang C, Feldman MJ, Wang H, Pang Y, Maggio DM, Zhu D, Nesvick CL, Dmitriev P, Bullova P, Chittiboina P, Brady RO, Pacak K, Zhuang Z.

Oncotarget. 2017 May 23;8(34):56110-56125. doi: 10.18632/oncotarget.18125. eCollection 2017 Aug 22.

8.

Mature Cystic Teratoma: AIRP Best Cases in Radiologic-Pathologic Correlation.

Bernot JM, Haeusler KA, Lisanti CJ, Brady RO, Ritchie BL.

Radiographics. 2017 Sep-Oct;37(5):1401-1407. doi: 10.1148/rg.2017170003.

PMID:
28898187
9.

Bipolar mood state reflected in cortico-amygdala resting state connectivity: A cohort and longitudinal study.

Brady RO Jr, Margolis A, Masters GA, Keshavan M, Öngür D.

J Affect Disord. 2017 Aug 1;217:205-209. doi: 10.1016/j.jad.2017.03.043. Epub 2017 Mar 28.

10.

Differential brain network activity across mood states in bipolar disorder.

Brady RO Jr, Tandon N, Masters GA, Margolis A, Cohen BM, Keshavan M, Öngür D.

J Affect Disord. 2017 Jan 1;207:367-376. doi: 10.1016/j.jad.2016.09.041. Epub 2016 Oct 6.

11.

Development of a model system for neuronal dysfunction in Fabry disease.

Kaneski CR, Brady RO, Hanover JA, Schueler UH.

Mol Genet Metab. 2016 Sep;119(1-2):144-50. doi: 10.1016/j.ymgme.2016.07.010. Epub 2016 Jul 22.

12.

State dependent cortico-amygdala circuit dysfunction in bipolar disorder.

Brady RO Jr, Masters GA, Mathew IT, Margolis A, Cohen BM, Öngür D, Keshavan M.

J Affect Disord. 2016 Sep 1;201:79-87. doi: 10.1016/j.jad.2016.04.052. Epub 2016 Apr 28.

13.

Emergent treatments based on the pathophysiology of bipolar disorder: A selective review.

Brady RO, Keshavan M.

Asian J Psychiatr. 2015 Dec;18:15-21. doi: 10.1016/j.ajp.2015.07.017. Epub 2015 Sep 28. Review.

14.

Activation of hypoxia signaling induces phenotypic transformation of glioma cells: implications for bevacizumab antiangiogenic therapy.

Xu H, Rahimpour S, Nesvick CL, Zhang X, Ma J, Zhang M, Zhang G, Wang L, Yang C, Hong CS, Germanwala AV, Elder JB, Ray-Chaudhury A, Yao Y, Gilbert MR, Lonser RR, Heiss JD, Brady RO, Mao Y, Qin J, Zhuang Z.

Oncotarget. 2015 May 20;6(14):11882-93.

15.

Mutant glucocerebrosidase in Gaucher disease recruits Hsp27 to the Hsp90 chaperone complex for proteasomal degradation.

Yang C, Wang H, Zhu D, Hong CS, Dmitriev P, Zhang C, Li Y, Ikejiri B, Brady RO, Zhuang Z.

Proc Natl Acad Sci U S A. 2015 Jan 27;112(4):1137-42. doi: 10.1073/pnas.1424288112. Epub 2015 Jan 12.

16.

Normalization and improvement of CNS deficits in mice with Hurler syndrome after long-term peripheral delivery of BBB-targeted iduronidase.

El-Amouri SS, Dai M, Han JF, Brady RO, Pan D.

Mol Ther. 2014 Dec;22(12):2028-37. doi: 10.1038/mt.2014.152. Epub 2014 Aug 4.

17.

Glucocerebrosidase 2 gene deletion rescues type 1 Gaucher disease.

Mistry PK, Liu J, Sun L, Chuang WL, Yuen T, Yang R, Lu P, Zhang K, Li J, Keutzer J, Stachnik A, Mennone A, Boyer JL, Jain D, Brady RO, New MI, Zaidi M.

Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):4934-9. doi: 10.1073/pnas.1400768111. Epub 2014 Mar 17.

18.

Platelets are efficient and protective depots for storage, distribution, and delivery of lysosomal enzyme in mice with Hurler syndrome.

Dai M, Han J, El-Amouri SS, Brady RO, Pan D.

Proc Natl Acad Sci U S A. 2014 Feb 18;111(7):2680-5. doi: 10.1073/pnas.1323155111. Epub 2014 Feb 3.

19.

Position statement: National Gaucher Foundation Medical Advisory Board, January 7, 2014.

Barranger JA, Brady RO, Grabowski GA, Mankin H, Mistry PK, Weinreb NJ.

Am J Hematol. 2014 May;89(5):457-8. doi: 10.1002/ajh.23687. Epub 2014 Mar 7. No abstract available.

20.

Celastrol increases glucocerebrosidase activity in Gaucher disease by modulating molecular chaperones.

Yang C, Swallows CL, Zhang C, Lu J, Xiao H, Brady RO, Zhuang Z.

Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):249-54. doi: 10.1073/pnas.1321341111. Epub 2013 Dec 18.

21.

99mTc-sestamibi scintigraphy to monitor the long-term efficacy of enzyme replacement therapy on bone marrow infiltration in patients with Gaucher disease.

Erba PA, Minichilli F, Giona F, Linari S, Dambrosia J, Pierini A, Filocamo M, Di Rocco M, Buffoni F, Brady RO, Mariani G.

J Nucl Med. 2013 Oct;54(10):1717-24. doi: 10.2967/jnumed.113.121871. Epub 2013 Aug 29.

22.

Are structural brain abnormalities associated with suicidal behavior in patients with psychotic disorders?

Giakoumatos CI, Tandon N, Shah J, Mathew IT, Brady RO, Clementz BA, Pearlson GD, Thaker GK, Tamminga CA, Sweeney JA, Keshavan MS.

J Psychiatr Res. 2013 Oct;47(10):1389-95. doi: 10.1016/j.jpsychires.2013.06.011. Epub 2013 Jul 15.

23.

Histone deacetylase inhibitors are neuroprotective and preserve NGF-mediated cell survival following traumatic brain injury.

Lu J, Frerich JM, Turtzo LC, Li S, Chiang J, Yang C, Wang X, Zhang C, Wu C, Sun Z, Niu G, Zhuang Z, Brady RO, Chen X.

Proc Natl Acad Sci U S A. 2013 Jun 25;110(26):10747-52. doi: 10.1073/pnas.1308950110. Epub 2013 Jun 10.

24.

Brain gamma-aminobutyric acid (GABA) abnormalities in bipolar disorder.

Brady RO Jr, McCarthy JM, Prescot AP, Jensen JE, Cooper AJ, Cohen BM, Renshaw PF, Ongür D.

Bipolar Disord. 2013 Jun;15(4):434-9. doi: 10.1111/bdi.12074. Epub 2013 May 2.

25.

Engineering a lysosomal enzyme with a derivative of receptor-binding domain of apoE enables delivery across the blood-brain barrier.

Wang D, El-Amouri SS, Dai M, Kuan CY, Hui DY, Brady RO, Pan D.

Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2999-3004. doi: 10.1073/pnas.1222742110. Epub 2013 Feb 4.

26.

Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones.

Yang C, Rahimpour S, Lu J, Pacak K, Ikejiri B, Brady RO, Zhuang Z.

Proc Natl Acad Sci U S A. 2013 Jan 15;110(3):966-71. doi: 10.1073/pnas.1221046110. Epub 2012 Dec 31.

27.

A longitudinal pilot proton MRS investigation of the manic and euthymic states of bipolar disorder.

Brady RO Jr, Cooper A, Jensen JE, Tandon N, Cohen B, Renshaw P, Keshavan M, Öngür D.

Transl Psychiatry. 2012 Sep 11;2:e160. doi: 10.1038/tp.2012.84.

28.

An innovative approach to the treatment of Gaucher disease and possibly other metabolic disorders of the brain.

Brady RO, Yang C, Zhuang Z.

J Inherit Metab Dis. 2013 May;36(3):451-4. doi: 10.1007/s10545-012-9515-9. Epub 2012 Jul 20. Review.

29.

β-Catenin signaling initiates the activation of astrocytes and its dysregulation contributes to the pathogenesis of astrocytomas.

Yang C, Iyer RR, Yu AC, Yong RL, Park DM, Weil RJ, Ikejiri B, Brady RO, Lonser RR, Zhuang Z.

Proc Natl Acad Sci U S A. 2012 May 1;109(18):6963-8. doi: 10.1073/pnas.1118754109. Epub 2012 Apr 13.

30.

Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease.

Lu J, Yang C, Chen M, Ye DY, Lonser RR, Brady RO, Zhuang Z.

Proc Natl Acad Sci U S A. 2011 Dec 27;108(52):21200-5. doi: 10.1073/pnas.1119181109. Epub 2011 Dec 12.

31.

The saccadic and neurological deficits in type 3 Gaucher disease.

Benko W, Ries M, Wiggs EA, Brady RO, Schiffmann R, Fitzgibbon EJ.

PLoS One. 2011;6(7):e22410. doi: 10.1371/journal.pone.0022410. Epub 2011 Jul 20.

32.

Missense mutations in the NF2 gene result in the quantitative loss of merlin protein and minimally affect protein intrinsic function.

Yang C, Asthagiri AR, Iyer RR, Lu J, Xu DS, Ksendzovsky A, Brady RO, Zhuang Z, Lonser RR.

Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):4980-5. doi: 10.1073/pnas.1102198108. Epub 2011 Mar 7.

33.

Development of enzyme replacement therapy for Fabry disease.

Schiffmann R, Brady RO.

In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 36.

34.

Possible future therapies for Fabry disease.

Brady RO, Schiffmann R.

In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 43.

35.

Decreased glucocerebrosidase activity in Gaucher disease parallels quantitative enzyme loss due to abnormal interaction with TCP1 and c-Cbl.

Lu J, Chiang J, Iyer RR, Thompson E, Kaneski CR, Xu DS, Yang C, Chen M, Hodes RJ, Lonser RR, Brady RO, Zhuang Z.

Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21665-70. doi: 10.1073/pnas.1014376107. Epub 2010 Nov 22.

36.

Benefits from unearthing "a biochemical Rosetta Stone".

Brady RO.

J Biol Chem. 2010 Dec 31;285(53):41216-21. doi: 10.1074/jbc.X110.197954. Epub 2010 Oct 28. No abstract available.

37.

Lysosomal alpha-galactosidase controls the generation of self lipid antigens for natural killer T cells.

Darmoise A, Teneberg S, Bouzonville L, Brady RO, Beck M, Kaufmann SH, Winau F.

Immunity. 2010 Aug 27;33(2):216-28. doi: 10.1016/j.immuni.2010.08.003.

38.

Use of lissamine rhodamine ceramide trihexoside as a functional assay for alpha-galactosidase A in intact cells.

Kaneski CR, Schiffmann R, Brady RO, Murray GJ.

J Lipid Res. 2010 Sep;51(9):2808-17. doi: 10.1194/jlr.D007294. Epub 2010 Jun 6.

39.

Induced pluripotent stem cells derived from mouse models of lysosomal storage disorders.

Meng XL, Shen JS, Kawagoe S, Ohashi T, Brady RO, Eto Y.

Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7886-91. doi: 10.1073/pnas.1002758107. Epub 2010 Apr 12.

40.

A validated disease severity scoring system for Fabry disease.

Giannini EH, Mehta AB, Hilz MJ, Beck M, Bichet DG, Brady RO, West M, Germain DP, Wanner C, Waldek S, Clarke JT, Mengel E, Strotmann JM, Warnock DG, Linhart A.

Mol Genet Metab. 2010 Mar;99(3):283-90. doi: 10.1016/j.ymgme.2009.10.178. Epub 2009 Oct 30.

PMID:
19951842
41.

Conditional deletion of neuronal cyclin-dependent kinase 5 in developing forebrain results in microglial activation and neurodegeneration.

Takahashi S, Ohshima T, Hirasawa M, Pareek TK, Bugge TH, Morozov A, Fujieda K, Brady RO, Kulkarni AB.

Am J Pathol. 2010 Jan;176(1):320-9. doi: 10.2353/ajpath.2010.081158. Epub 2009 Nov 30.

42.

Gaucher disease: resetting the clinical and scientific agenda.

Mistry PK, Weinreb NJ, Brady RO, Grabowski GA.

Am J Hematol. 2009 Apr;84(4):205-7. doi: 10.1002/ajh.21384. No abstract available.

43.

WITHDRAWN: Familial Degenerative Encephalopathy with Intracranial Calcification and Metaphyseal Dysplasia.

Timmons MM, Garbern J, Robey PG, Singleton A, Hernandez DG, Roodman GD, Zaltz I, Mumm S, Wilcox W, Fischbeck KH, Brady RO, Knight MA.

J Bone Miner Res. 2008 Nov 18. [Epub ahead of print]

44.

Skin-impedance in Fabry Disease: a prospective, controlled, non-randomized clinical study.

Gupta SN, Ries M, Murray GJ, Quirk JM, Brady RO, Lidicker JR, Schiffmann R, Moore DF.

BMC Neurol. 2008 Nov 6;8:41. doi: 10.1186/1471-2377-8-41.

45.

Neurophysiological, behavioral and morphological abnormalities in the Fabry knockout mice.

Rodrigues LG, Ferraz MJ, Rodrigues D, Pais-Vieira M, Lima D, Brady RO, Sousa MM, Sá-Miranda MC.

Neurobiol Dis. 2009 Jan;33(1):48-56. doi: 10.1016/j.nbd.2008.09.001. Epub 2008 Sep 23.

PMID:
18848893
46.

Prediction of response of mutated alpha-galactosidase A to a pharmacological chaperone.

Shin SH, Kluepfel-Stahl S, Cooney AM, Kaneski CR, Quirk JM, Schiffmann R, Brady RO, Murray GJ.

Pharmacogenet Genomics. 2008 Sep;18(9):773-80. doi: 10.1097/FPC.0b013e32830500f4.

47.

A new severity score index for phenotypic classification and evaluation of responses to treatment in type I Gaucher disease.

Di Rocco M, Giona F, Carubbi F, Linari S, Minichilli F, Brady RO, Mariani G, Cappellini MD.

Haematologica. 2008 Aug;93(8):1211-8. doi: 10.3324/haematol.12379. Epub 2008 Jul 4.

48.

Apoptotic abnormalities in differential gene expression in peripheral blood mononuclear cells from children with Fabry disease.

Moore DF, Goldin E, Gelderman MP, Robinson C, Baer J, Ries M, Elkahloun A, Brady RO, Schiffmann R.

Acta Paediatr. 2008 Apr;97(457):48-52. doi: 10.1111/j.1651-2227.2008.00654.x.

PMID:
18339188
49.

Elevated globotriaosylsphingosine is a hallmark of Fabry disease.

Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, van Roomen C, Mirzaian M, Wijburg FA, Linthorst GE, Vedder AC, Rombach SM, Cox-Brinkman J, Somerharju P, Boot RG, Hollak CE, Brady RO, Poorthuis BJ.

Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):2812-7. doi: 10.1073/pnas.0712309105. Epub 2008 Feb 19.

50.

Chemical chaperone therapy: clinical effect in murine G(M1)-gangliosidosis.

Suzuki Y, Ichinomiya S, Kurosawa M, Ohkubo M, Watanabe H, Iwasaki H, Matsuda J, Noguchi Y, Takimoto K, Itoh M, Tabe M, Iida M, Kubo T, Ogawa S, Nanba E, Higaki K, Ohno K, Brady RO.

Ann Neurol. 2007 Dec;62(6):671-5.

PMID:
17994547

Supplemental Content

Loading ...
Support Center